comprehensive -WSS

comprehensive

author：leisure time 2025-09-29 21:28:14 - browse：15

A liver with a smooth and healthy left half and a bumpy, browning right half — chronic disease coverage from STAT — Adobe

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients — most notably reductions in liver scarring at a rate three times higher than placebo without worsening other symptoms.

The mid-stage study of the Akero drug called efruxifermin achieved its main goal in September 2022. With longer treatment, more patients with MASH responded to the drug, while those who initially benefited showed durable improvements.

“We’re really pleased with the data. It’s exactly what we were hoping to see,” said Kitty Yale, Akero’s chief development officer, in an interview with STAT. “It’s not just the high response rates, but the fact that responses are sustained and broadened as well.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： DeSantis wants to import drugs. Biden’s FDA blasted his plan

focus

WSS

Intarcia’s device

CDC advisers recommend seasonal use of Pfizer RSV shot

CDC's new outbreak response network to include Northeastern

Thermo Fisher plant for manufacturing gene therapies to expand

Senators: Long

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

focus

comprehensive

hotspot

23andMe had bad news about my health. I wish a person had delivered it

Readout LOUD podcast: possible new ALS drug, artificial wombs

Tori Bowie and the unacceptable rates of Black maternal death

Second xenotransplant done with gene

Drug repurposing or repositioning? The language matters

FDA greenlights medical device to combat bladder issues

Activists slam private health insurers over coverage restrictions

Former Pear Therapeutics executives start new VC firm

Cancer drug shortages should be causing more outrage

PBMs are inflating the cost of generic drugs. They must be reined in

hotspot

As obesity drug market grows, telehealth companies court payers

Senate HELP committee spars over health care workforce policies

Hearing on Medicare drug price negotiation gets unusually heated

Trans patients at the end of life deserve respect and dignity

Meadows told special counsel he could not recall Trump ever declassifying Mar

Republicans love RFK Jr. What's that tell us about health in 2024?

focus

entertainment

focus

knowledge